LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | WZ-4-145 | 0.12 | uM | LJP6 | 72 | hr | 1311 | 4569 | 5013 | 0.9113 | 0.8799 |
MDA-MB-231 | XMD16-144 | 0.12 | uM | LJP5 | 72 | hr | 1311 | 1577 | 5013 | 0.3146 | 0.0718 |
MDA-MB-231 | Brivanib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4947 | 5013 | 0.9868 | 0.9821 |
MDA-MB-231 | Buparlisib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4960 | 5013 | 0.9895 | 0.9857 |
MDA-MB-231 | BX-912 | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4923 | 5013 | 0.9821 | 0.9757 |
MDA-MB-231 | Canertinib | 0.12 | uM | LJP6 | 72 | hr | 1311 | 4785 | 5013 | 0.9545 | 0.9384 |
MDA-MB-231 | Celastrol | 0.12 | uM | LJP6 | 72 | hr | 1311 | 4980 | 5013 | 0.9934 | 0.9910 |
MDA-MB-231 | CGP60474 | 0.12 | uM | LJP5 | 72 | hr | 1311 | 1271 | 5013 | 0.2537 | -0.0108 |
MDA-MB-231 | CGP60474 | 0.12 | uM | LJP6 | 72 | hr | 1311 | 791 | 5013 | 0.1578 | -0.1406 |
MDA-MB-231 | CHIR-99021 | 0.12 | uM | LJP6 | 72 | hr | 1311 | 4267 | 5013 | 0.8512 | 0.7985 |
MDA-MB-231 | CP724714 | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4723 | 5013 | 0.9421 | 0.9216 |
MDA-MB-231 | CP466722 | 0.12 | uM | LJP5 | 72 | hr | 1311 | 5059 | 5013 | 1.0091 | 1.0124 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4560 | 5013 | 0.9095 | 0.8775 |
MDA-MB-231 | Momelotinib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4298 | 5013 | 0.8574 | 0.8069 |
MDA-MB-231 | Dasatinib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 1229 | 5013 | 0.2451 | -0.0223 |
MDA-MB-231 | Dasatinib | 0.12 | uM | LJP6 | 72 | hr | 1311 | 899 | 5013 | 0.1793 | -0.1115 |
MDA-MB-231 | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4826 | 5013 | 0.9627 | 0.9494 |
MDA-MB-231 | Enzastaurin | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4986 | 5013 | 0.9945 | 0.9926 |
MDA-MB-231 | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4941 | 5013 | 0.9857 | 0.9806 |
MDA-MB-231 | Foretinib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 3313 | 5013 | 0.6608 | 0.5406 |
MDA-MB-231 | R406 | 0.12 | uM | LJP6 | 72 | hr | 1311 | 4919 | 5013 | 0.9813 | 0.9747 |
MDA-MB-231 | Pictilisib | 0.12 | uM | LJP6 | 72 | hr | 1311 | 4253 | 5013 | 0.8484 | 0.7947 |
MDA-MB-231 | Gefitinib | 0.12 | uM | LJP6 | 72 | hr | 1311 | 5020 | 5013 | 1.0014 | 1.0018 |
MDA-MB-231 | Geldanamycin | 0.12 | uM | LJP5 | 72 | hr | 1311 | 1743 | 5013 | 0.3478 | 0.1167 |
MDA-MB-231 | Geldanamycin | 0.12 | uM | LJP6 | 72 | hr | 1311 | 1521 | 5013 | 0.3034 | 0.0565 |